NVS NOVARTIS AG IFRS
Pharmaceutical Preparations · NYSE · SEC CIK 1114448 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 | 2020Q22020-06-30 | 2019Q22019-06-30 | 2018Q22018-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $14.05B | $12.51B | $11.44B | $12.78B | $12.96B | $11.35B | $11.76B | $11.36B |
| Cost of revenue | $3.32B | $3.17B | $3.34B | $3.75B | $3.91B | $3.43B | $3.41B | $3.56B |
| Gross profit | $11.51B | $9.70B | $8.40B | $9.33B | $9.38B | $8.19B | $8.62B | $8.10B |
| R&D expense | $2.73B | $2.37B | $2.30B | $2.50B | $2.40B | $2.44B | $2.05B | $2.13B |
| SG&A expense | $3.44B | $3.09B | $3.09B | $3.58B | $3.75B | $3.37B | $3.58B | $3.50B |
| Operating income | $4.86B | $4.01B | $2.81B | $2.23B | $3.48B | $2.35B | $2.66B | $2.43B |
| Interest expense | $289.00M | $246.00M | $216.00M | $202.00M | $201.00M | $220.00M | $205.00M | $237.00M |
| Pretax income | $4.53B | $3.84B | $2.67B | $2.04B | $3.51B | $2.29B | $2.63B | $8.17B |
| Income tax | $507.00M | $595.00M | $403.00M | $347.00M | $611.00M | $421.00M | $525.00M | $443.00M |
| Net income | $4.04B | $3.25B | $2.32B | $1.69B | $2.90B | $1.87B | $6.80B | $7.77B |
| EPS (basic) | 2.07 | 1.60 | 1.11 | 0.77 | 1.29 | 0.82 | 2.94 | 3.34 |
| EPS (diluted) | 2.06 | 1.59 | 1.11 | 0.77 | 1.28 | 0.81 | 2.91 | 3.31 |
| Weighted avg. shares (diluted) | 1.96B | 2.05B | 2.10B | 2.21B | 2.26B | 2.30B | 2.33B | 2.35B |
| Balance sheet | ||||||||
| Cash & equivalents | $6.66B | $7.90B | $10.88B | $3.62B | $5.12B | $5.92B | $9.99B | $12.45B |
| Receivables | $9.06B | $8.23B | $9.20B | $8.64B | $8.40B | $7.64B | $7.97B | $8.80B |
| Inventory | $6.31B | $5.75B | $8.23B | $6.88B | $7.11B | $6.90B | $6.09B | $7.10B |
| Current assets | $25.94B | $25.69B | $33.49B | $38.14B | $23.81B | $23.88B | $28.32B | $32.06B |
| PP&E, netmay include right-of-use assets (IFRS) | $10.38B | $9.25B | $10.82B | $10.73B | $11.74B | $11.96B | $12.29B | $15.96B |
| Goodwill | $25.55B | $25.23B | $29.52B | $29.11B | $29.77B | $29.10B | $26.53B | $35.17B |
| Intangibles | $29.24B | $27.77B | $28.00B | $33.37B | $34.82B | $36.67B | $27.22B | $39.44B |
| Total assets | $104.39B | $97.50B | $110.98B | $122.91B | $124.02B | $123.76B | $116.29B | $142.06B |
| Current liabilities | $31.71B | $27.61B | $31.91B | $27.65B | $29.63B | $29.38B | $30.11B | $27.94B |
| Total liabilities | $62.34B | $55.60B | $59.05B | $59.90B | $69.89B | $69.88B | $64.79B | $65.16B |
| Shareholders' equity | $41.98B | $41.73B | $51.85B | $62.92B | $54.04B | $53.81B | $51.43B | $76.81B |
| Shares outstanding | — | — | — | — | — | — | — | 2.32B |
| Cash flow statement | ||||||||
| Operating cash flow | $6.66B | $4.88B | $3.58B | $3.75B | $4.13B | $3.96B | $3.11B | $3.94B |
| Capital expenditure | $331.00M | $260.00M | $225.00M | $257.00M | $321.00M | $238.00M | $279.00M | $257.00M |
| Free cash flow | $6.33B | $4.62B | $3.35B | $3.50B | $3.81B | $3.72B | $2.83B | $3.69B |
| Investing cash flow | -$2.24B | -$3.21B | -$1.05B | -$11.63B | $97.00M | -$425.00M | -$474.00M | $4.33B |
| Financing cash flow | -$5.21B | -$3.20B | -$3.64B | -$2.30B | -$2.94B | -$2.19B | -$28.00M | -$1.53B |
| Stock-based compensation | $267.00M | $257.00M | $222.00M | $204.00M | $185.00M | $199.00M | $174.00M | $155.00M |
| Dividends paid | $2.48B | $2.42B | — | — | — | — | — | — |
| Share buybacks | $2.71B | $1.62B | $2.96B | $2.71B | $703.00M | $9.00M | $2.37B | $599.00M |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.